|
1
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: review on morphology, molecular pathology,
prognosis, and differential diagnosis. Arch Pathol Lab Med.
130:1466–1478. 2006.PubMed/NCBI
|
|
2
|
Meng L, Fang SH and Jin M: An unusual case
of pancreatic and gastric neoplasms (2010: 12b). Malignant GISTs
originating from the pancreas and stomach. Eur Radiol. 21:663–665.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huizinga JD, Thuneberg L, Klüppel M,
Malysz J, Mikkelsen HB and Bernstein A: W/kit gene required for
interstitial cells of Cajal and for intestinal pacemaker activity.
Nature. 373:347–349. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sarlomo-Rikala M, Kovatich AJ,
Barusevicius A and Miettinen M: CD117: a sensitive marker for
gastrointestinal stromal tumors that is more specific than CD34.
Mod Pathol. 11:728–734. 1998.PubMed/NCBI
|
|
5
|
Fletcher CD, Berman JJ, Corless C,
Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti
H, Rubin BP, et al: Diagnosis of gastrointestinal stromal tumors: A
consensus approach. Hum Pathol. 33:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rubin BP, Singer S, Tsao C, Duensing A,
Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, et al: KIT
activation is a ubiquitous feature of gastrointestinal stromal
tumors. Cancer Res. 61:8118–8121. 2001.PubMed/NCBI
|
|
8
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirota S, Ohashi A, Nishida T, Isozaki K,
Kinoshita K, Shinomura Y and Kitamura Y: Gain-of-function mutations
of platelet-derived growth factor receptor alpha gene in
gastrointestinal stromal tumors. Gastroenterology. 125:660–667.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Demetri GD, von Mehren M, Blanke CD, Van
den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA,
Singer S, Janicek M, et al: Efficacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. N Engl J Med.
347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Oosterom AT, Judson I, Verweij J,
Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A,
Sciot R, Van Glabbeke M, Silberman S and Nielsen OS; European
Organisation for Research and Treatment of Cancer Soft Tissue and
Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in
metastatic gastrointestinal stromal tumours: a phase I study.
Lancet. 358:1421–1423. 2001.PubMed/NCBI
|
|
13
|
Tamborini E, Bonadiman L, Greco A,
Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali
PG, Pierotti MA and Pilotti S: A new mutation in the KIT ATP pocket
causes acquired resistance to imatinib in a gastrointestinal
stromal tumor patient. Gastroenterology. 127:294–299. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buchdunger E, Cioffi CL, Law N, Stover D,
Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase
inhibitor STI571 inhibits in vitro signal transduction mediated by
c-kit and platelet-derived growth factor receptors. J Pharmacol Exp
Ther. 295:139–145. 2002.
|
|
15
|
Waller CF: Imatinib mesylate. Recent
Results Cancer Res. 184:3–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cassier PA and Blay JY: Imatinib mesylate
for the treatment of gastrointestinal stromal tumor. Expert Rev
Anticancer Ther. 10:623–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lopes LF and Bacchi CE: Imatinib treatment
for gastrointestinal stromal tumour (GIST). J Cell Mol Med.
14:42–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marin D: Current status of imatinib as
frontline therapy for chronic myeloid leukemia. Semin Hematol.
47:312–318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mauro MJ and Druker BJ: STI571: targeting
BCR-ABL as therapy for CML. Oncologist. 6:233–238. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Casali PG, Messina A, Stacchiotti S,
Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico
C, Bertieri R, et al: Imatinib mesylate in chordoma. Cancer.
101:2086–2097. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kérob D, Porcher R, Vérola O, Dalle S,
Maubec E, Aubin F, D'Incan M, Bodokh I, Boulinguez S,
Madelaine-Chambrin I, et al: Imatinib mesylate as a preoperative
therapy in dermatofibrosarcoma: results of a multicenter phase II
study on 25 patients. Clin Cancer Res. 16:3288–3295.
2010.PubMed/NCBI
|
|
22
|
Heinrich MC, Corless CL, Demetri GD,
Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den
Abbeele AD, Druker BJ, et al: Kinase mutations and imatinib
response in patients with metastatic gastrointestinal stromal
tumor. J Clin Oncol. 21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Corless CL, Schroeder A, Griffith D, Town
A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J and
Heinrich MC: PDGFRA mutations in gastrointestinal stromal tumors:
frequency, spectrum and in vitro sensitivity to imatinib. J Clin
Oncol. 23:5357–5364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang L, Bai CG, Hou XW, Liu XH and Ma DL:
Transforming effect of PDGFRA gene mutant on the cell function in
gastrointestinal stromal tumor. Zhonghua Zhong Liu Za Zhi.
31:500–504. 2009.(In Chinese).
|
|
25
|
Lasota J and Miettinen M: Clinical
significance of oncogenic KIT and PDGFRA mutations in
gastrointestinal stromal tumours. Histopathology. 53:245–266. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lasota J and Miettinen M: KIT and PDGFRA
mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn
Pathol. 23:91–102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frost MJ, Ferrao PT, Hughes TP and Ashman
LK: Juxtamembrane mutant V560GKit is more sensitive to Imatinib
(STI571) compared with wild-type c-kit whereas the kinase domain
mutant D816VKit is resistant. Mol Cancer Ther. 1:1115–1124.
2002.PubMed/NCBI
|
|
28
|
Merkelbach-Bruse S, Dietmaier W, Füzesi L,
Gaumann A, Haller F, Kitz J, Krohn A, Mechtersheimer G, Penzel R,
Schildhaus HU, et al: Pitfalls in mutational testing and reporting
of common KIT and PDGFRA mutations in gastrointestinal stromal
tumors. BMC Med Genet. 11:1062010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Demetri GD, Wang Y, Wehrle E, Racine A,
Nikolova Z, Blanke CD, Joensuu H and von Mehren M: Imatinib plasma
levels are correlated with clinical benefit in patients with
unresectable/metastatic gastrointestinal stromal tumors. J Clin
Oncol. 27:3141–3147. 2009. View Article : Google Scholar : PubMed/NCBI
|
